Loading...
Please wait, while we are loading the content...
Similar Documents
Faecal Microbiota Transplantation and Chronic Kidney Disease
| Content Provider | MDPI |
|---|---|
| Author | Bian, Ji Liebert, Ann Bicknell, Brian Chen, Xin-Ming Huang, Chunling Pollock, Carol A. |
| Copyright Year | 2022 |
| Description | Faecal microbiota transplantation (FMT) has attracted increasing attention as an intervention in many clinical conditions, including autoimmune, enteroendocrine, gastroenterological, and neurological diseases. For years, FMT has been an effective second-line treatment for Clostridium difficile infection (CDI) with beneficial outcomes. FMT is also promising in improving bowel diseases, such as ulcerative colitis (UC). Pre-clinical and clinical studies suggest that this microbiota-based intervention may influence the development and progression of chronic kidney disease (CKD) via modifying a dysregulated gut–kidney axis. Despite the high morbidity and mortality due to CKD, there are limited options for treatment until end-stage kidney disease occurs, which results in death, dialysis, or kidney transplantation. This imposes a significant financial and health burden on the individual, their families and careers, and the health system. Recent studies have suggested that strategies to reverse gut dysbiosis using FMT are a promising therapy in CKD. This review summarises the preclinical and clinical evidence and postulates the potential therapeutic effect of FMT in the management of CKD. |
| Starting Page | 2528 |
| e-ISSN | 20726643 |
| DOI | 10.3390/nu14122528 |
| Journal | Nutrients |
| Issue Number | 12 |
| Volume Number | 14 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2022-06-17 |
| Access Restriction | Open |
| Subject Keyword | Nutrients Gastroenterology and Hepatology Faecal Microbiota Transplantation Chronic Kidney Disease Gut Microbial Metabolites Gut Barrier Immunity/inflammation |
| Content Type | Text |
| Resource Type | Article |
